Alopecia areata causes and the first FDA-approved oral treatment
أسباب ثعلبة الرأس وطرق علاجها مع د. ماهر محمود
- Broadcast
- Program
- Al-Setat
About this appearance
Full 18-minute studio interview discussing the June 2022 FDA approval of the first oral JAK inhibitor (baricitinib / Olumiant, 4 mg daily for 6 months with >80% regrowth in severe alopecia areata clinical trials of 1,200 patients), alongside summer hair care and PRP tube quality.
General information, not a diagnosis. For advice about your own skin, book a consultation. Book a consultation
